Neuroimaging findings in mild cognitive impairment

Flavio Nobili, Dario Arnaldi, Luca Roccatagliata, Jennifer Accardo, Agnese Picco, Michela Ferrara

Research output: Chapter in Book/Report/Conference proceedingChapter


The clinical construct of mild cognitive impairment (MCI) identifi es a syndrome of cognitive defi cit without dementia, whose fate is unpredictable without an effort to establish the underlying cause. MCI is the natural “reservoir” of subsequent dementing illnesses, but it can be provoked by a variety of psychiatric and systemic diseases as well as by drugs, alcohol, and substance abuse. In this context, morphological and, especially, functional neuroimaging by means of multitracer SPECT and PET provide clue information on the underlying pathological process. Both MRI and SPECT/PET have been included as biomarkers in the revised criteria for the diagnosis of Alzheimer’s disease before dementia; similarly, dopamine transporter SPECT and FDG-PET are supportive features for the diagnosis of cognitive defi cit due to diffuse Lewy-body disease or to frontotemporal lobe degeneration, respectively. The advent of amyloid imaging with PET radiopharmaceuticals has paved the way to the noninvasive brain biopsy for beta amyloid and can detect amyloidosis in otherwise healthy individuals. In the advanced memory clinics, appropriate use of neuroimaging is nowadays the cornerstone of correct diagnosis of cognitive disorders. New developments include high-fi eld MRI equipment, new fl uorinated PET radiopharmaceuticals for amyloid detection and receptor studies, and the upcoming tool of MRI-PET.

Original languageEnglish
Title of host publicationPet and Spect in Neurology
PublisherSpringer Berlin Heidelberg
Number of pages37
ISBN (Electronic)9783642543074
ISBN (Print)9783642543067
Publication statusPublished - Jan 1 2014

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Neuroimaging findings in mild cognitive impairment'. Together they form a unique fingerprint.

Cite this